Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.

Authors

Özlem Coşkun

Published in

Cell biochemistry and biophysics. Sep 08, 2026. Epub Sep 08, 2026.

Abstract

CD38 is a type II transmembrane glycoprotein and serves as the primary ectoenzyme responsible for regulating cellular nicotinamide adenine dinucleotide (NAD⁺⁾ levels in mammalian tissues. Initially identified as a lymphocyte activation marker, recent research has revealed its significant role in immunosuppression within oncological processes, NAD⁺ depletion associated with aging, and exosomal signaling. This review provides a comprehensive analysis of the enzymatic functions of CD38, its pathophysiological impacts on both hematological and solid tumors, and the mechanisms of resistance that emerge against anti-CD38 therapies. Furthermore, the potential of CD38 as an exosomal biomarker in liquid biopsy procedures and its function as a "metabolic resetter" for promoting healthy aging are explored.

PMID:
42709393
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.